Why Eli Lilly Is Underrated in the Red-Hot GLP-1 Weight-Loss Drug Race, per Morgan Stanley May 25, 2026 Life Science
Pfizer’s 50% Stock Crash: A Hidden Contrarian Buy Amid Booming Healthcare Sector May 22, 2026 Life Science
Can Viking Therapeutics Replicate Eli Lilly’s Success in the Weight-Loss Drug Market? May 21, 2026 Life Science
With the Macroeconomic Environment Improving, these Three Biotech Stocks Are Worth Watching May 21, 2026 Life Science
Dyne Therapeutics Stock Rises 40% in a Year, but Saturn V Fund Reduces Holdings May 20, 2026 Life Science
Bullish on Oncology Drug Potential? This Biotech Fund Increases Stake in Enliven Therapeutics May 13, 2026 Life Science
Can Novo Nordisk Stage a Turnaround on Wegovy Data and Robust Drug Pipeline? May 13, 2026 Life Science
Pfizer’s 6.7% Dividend: Can It Survive Plunging Profits and Cash Flow Crunch? May 12, 2026 Life Science
Hantavirus Fears Fuel Moderna Rally: Is This a Real Catalyst or Just Sentiment? May 11, 2026 Life Science
Eli Lilly’s Alzheimer’s Drug Kisunla Wins Health Canada Approval, Bolstering Global Footprint May 4, 2026 Life Science
GLP-1s and AI Are the Big Themes Behind These 5 Top-Rated Health Care Picks for 2026 May 4, 2026 Life Science
